Turtle Creek Asset Management Inc. Increases Position in Medpace Holdings, Inc. $MEDP

Turtle Creek Asset Management Inc. increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4,741.8% during the 1st quarter, Holdings Channel reports. The firm owned 135,570 shares of the company’s stock after acquiring an additional 132,770 shares during the period. Medpace comprises 2.4% of Turtle Creek Asset Management Inc.’s investment portfolio, making the stock its 19th biggest position. Turtle Creek Asset Management Inc.’s holdings in Medpace were worth $65,099,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of MEDP. NewEdge Advisors LLC boosted its holdings in Medpace by 22.1% in the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after buying an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after buying an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. raised its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Sivia Capital Partners LLC bought a new stake in Medpace during the second quarter valued at about $296,000. Finally, M&T Bank Corp lifted its position in shares of Medpace by 3.4% in the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after acquiring an additional 31 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling at Medpace

In other news, VP Susan E. Burwig sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the sale, the vice president directly owned 62,984 shares of the company’s stock, valued at $37,790,400. This represents a 10.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO August J. Troendle sold 3,728 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $600.85, for a total value of $2,239,968.80. Following the transaction, the chief executive officer owned 642,456 shares of the company’s stock, valued at $386,019,687.60. This represents a 0.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 31,087 shares of company stock worth $16,203,054 in the last quarter. 20.50% of the stock is owned by corporate insiders.

Medpace Stock Up 2.5%

MEDP opened at $585.49 on Thursday. The firm has a 50-day simple moving average of $501.76 and a two-hundred day simple moving average of $493.30. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The company has a market capitalization of $16.34 billion, a PE ratio of 34.32, a price-to-earnings-growth ratio of 2.55 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter last year, the business posted $3.10 earnings per share. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Royal Bank Of Canada upped their price objective on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and lifted their target price for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Barclays set a $600.00 price target on Medpace in a report on Thursday, July 23rd. Truist Financial upped their price target on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $535.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Two equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.